AI Analysis | Feedback

Here are 1-3 brief analogies to describe Savara (SVRA):

• An early-stage **Moderna**, but focused on developing treatments for rare lung diseases.
• A clinical-stage **Vertex Pharmaceuticals**, specializing in treatments for rare respiratory conditions.

AI Analysis | Feedback

• molgramostim: An inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for the treatment of autoimmune pulmonary alveolar proteinosis.

AI Analysis | Feedback

Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company with its lead product candidate, molgramostim, currently in Phase III development. As such, the company does not yet have commercial products approved for sale on the market.

Therefore, Savara Inc. does not have major customers, either other companies or individual consumers, from the sale of its products at this time.

AI Analysis | Feedback

• Recipharm Monts (affiliate of Recipharm AB)

AI Analysis | Feedback

Matthew Pauls, J.D., M.B.A. Chairman of the Board, Chief Executive Officer

Mr. Pauls has served as Chairman of the Board of Directors and Chief Executive Officer of Savara since 2020. From 2014 to 2019, he was President and Chief Executive Officer and a board member of Strongbridge Biopharma plc, a publicly traded rare disease biopharmaceutical company that he took public via an IPO on NASDAQ. Prior to 2014, he was Chief Commercial Officer of Insmed, Inc. and held senior commercial leadership positions at Shire Pharmaceuticals, Bristol Myers Squibb, and Johnson & Johnson. He currently serves as Lead Independent Director at Soleno Therapeutics and on the boards of Pelthos Therapeutics (both publicly traded biopharmaceutical companies), and Amplo Biotechnology (a private gene therapy company). He also co-founded a non-profit organization, WE R1.

David L. Lowrance, CPA Chief Financial and Administrative Officer, Secretary

Mr. Lowrance has served as Savara's Chief Financial and Administrative Officer since December 2022 and Chief Financial Officer since November 2016. Previously, Mr. Lowrance was Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals. Prior to that, he was Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company, where he led a $162 million international IPO. From 2003 to 2011, he served as Vice President and CFO of Cumberland Pharmaceuticals Inc., where he led an $85 million IPO with a NASDAQ listing in 2009.

Robert Lutz Chief Operating Officer

Mr. Lutz was appointed Chief Operating Officer in February 2023. He brings nearly two decades of operational leadership experience in the pharmaceutical industry. Prior to joining Savara, Mr. Lutz was Chief Financial and Business Officer of iBio, Inc., and previously served as Chief Financial Officer and Chief Business Officer of Strongbridge Biopharma plc. He also held leadership roles at Shire Plc. and Cinergy Corp.

Anne Erickson Chief Business Officer

Ms. Erickson serves as the Chief Business Officer for Savara Inc.

Yasmine Wasfi, M.D., Ph.D., FCCP Chief Medical Officer

Dr. Wasfi serves as the Chief Medical Officer, a position to which she was promoted in October 2025. She brings two decades of experience in healthcare and pulmonology.

AI Analysis | Feedback

1. Reliance on Molgramostim and Regulatory/Commercialization Risks: Savara's business heavily depends on the successful development, regulatory approval, and commercialization of its sole lead product candidate, molgramostim, for autoimmune pulmonary alveolar proteinosis (aPAP). The company faces substantial risks, including potential regulatory delays, uncertainties in clinical research, and challenges in obtaining regulatory approvals, as demonstrated by past setbacks like a "refuse-to-file" letter from the FDA. Failure to secure necessary approvals or market acceptance would significantly impact the company's ability to generate revenue and could jeopardize its long-term viability.
2. Ongoing Operating Losses and Need for Additional Capital: Savara has incurred significant operating losses since its inception and is projected to continue doing so until commercialization. The company's future viability depends on its ability to raise additional capital on acceptable terms. A failure to obtain sufficient financing could lead to delays, limitations, or termination of product development efforts and operations, and future equity issuances could dilute current shareholders.
3. Market Access, Competition, and Pricing Challenges: Even if molgramostim receives regulatory approval, Savara faces significant hurdles in securing market access and reimbursement, especially given the rarity of aPAP and the potential for high treatment costs. The company must navigate a complex regulatory environment and ensure favorable pricing and coverage. Additionally, the emergence of new competitors or breakthrough treatments in the rare respiratory disease space could challenge Savara's market position and revenue potential.

AI Analysis | Feedback

AI Analysis | Feedback

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Savara Inc. (SVRA) over the next 2-3 years:

1. U.S. Regulatory Approval and Commercial Launch of MOLBREEVI: The primary driver of future revenue growth for Savara is the anticipated U.S. Food and Drug Administration (FDA) approval and subsequent commercial launch of MOLBREEVI (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The FDA has granted Priority Review for MOLBREEVI, setting a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026. As there are currently no approved therapeutics for aPAP in the U.S., the successful launch of MOLBREEVI is expected to address a high unmet medical need and become a significant revenue generator.
2. European Regulatory Approval and Commercial Launch of MOLBREEVI: Savara plans to submit marketing authorization applications for MOLBREEVI to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026. Similar to the U.S. market, Europe represents a robust market opportunity with no approved therapies for aPAP, indicating that European commercialization will contribute significantly to future revenue growth following regulatory clearance.
3. Strong Market Penetration and Adoption Due to Unmet Need: MOLBREEVI is poised to be the first pharmacologic treatment option for aPAP in both the United States and Europe, a rare disease characterized by a high unmet medical need. Positive Phase 3 clinical trial results, coupled with the absence of approved therapies, suggest a substantial market potential, with analysts projecting global peak sales of up to $1.6 billion. This "first-in-class" status and the well-defined patient population are expected to drive a strong adoption rate, surpassing current off-label uses and accelerating revenue generation.

AI Analysis | Feedback

Share Issuance

• Savara closed a public offering of common stock and pre-funded warrants in October 2025, generating approximately $149.5 million in gross proceeds.
• The proceeds from the October 2025 offering are designated for general corporate purposes, including funding clinical development, regulatory approval for MOLBREEVI, commercialization infrastructure, supply, commercial launch preparation in the US and EU, and general and administrative expenses.
• In Q3 2024, Savara completed a significant common equity issuance, raising about $118.2 million, which enhanced its liquidity and balance sheet equity.

Inbound Investments

• In January 2026, Savara amended its loan agreement with Hercules Capital, Inc., securing access to an additional $75 million in funding, contingent upon FDA approval of MOLBREEVI.
• This additional $75 million, combined with a previous $75 million royalty financing agreement with RTW, provides Savara with approximately $150 million in non-dilutive capital to support launch activities upon FDA approval of MOLBREEVI.
• In March 2025, Savara entered a loan and security agreement with Hercules Capital, Inc. for up to $200 million, with an initial $30 million funded to refinance existing debt.

Capital Expenditures

• For the trailing 12 months, capital expenditures were reported as -$11K.
• Annual Capital Expenditures (CapEx) were reported as $0.01 million, $0.30 million, and $0.03 million in various periods.
• The company's operational strategy continues to rely on outsourced manufacturing and clinical operations, with primary operational cost drivers being research and development and regulatory activities.